anika_new_logo_highres_360x133 (002) (1).png
Anika Announces CFO Transition
08 mai 2024 16h08 HE | Anika Therapeutics Inc.
BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed...
anika_new_logo_highres_360x133 (002) (1).png
Anika Reports First Quarter 2024 Financial Results
08 mai 2024 16h05 HE | Anika Therapeutics Inc.
Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30...
anika_new_logo_highres_360x133 (002) (1).png
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mai 2024 16h01 HE | Anika Therapeutics Inc.
BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 1, 2024,...
anika_new_logo_highres_360x133 (002) (1).png
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
18 avr. 2024 16h01 HE | Anika Therapeutics Inc.
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company...
anika_new_logo_highres_360x133 (002) (1).png
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
02 avr. 2024 08h00 HE | Anika Therapeutics Inc.
BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management...
anika_new_logo_highres_360x133 (002) (1).png
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
13 mars 2024 16h05 HE | Anika Therapeutics Inc.
Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost...
anika_new_logo_highres_360x133 (002) (1).png
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 mars 2024 16h01 HE | Anika Therapeutics Inc.
BEDFORD, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on March 1,...
anika_new_logo_highres_360x133 (002) (1).png
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
27 févr. 2024 16h01 HE | Anika Therapeutics Inc.
BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company...
anika_new_logo_highres_360x133 (002) (1).png
Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
13 févr. 2024 09h00 HE | Anika Therapeutics Inc.
Announcing the limited market release of X-Twist™ Fixation System with biocomposite suture anchor for rotator cuff and other soft tissue repair at AAOS Focusing on its full Regenerative, Sports...
anika_new_logo_highres_360x133 (002) (1).png
Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
28 nov. 2023 09h00 HE | Anika Therapeutics Inc.
Integrity marks Anika’s entrance into the fast-growing $150 million+2 U.S. rotator cuff augmentation market and expansion of its proprietary hyaluronic acid (HA) regenerative portfolio BEDFORD,...